MaxCyte, Inc. provided revenue guidance for the full year 2022. For the period, the company expected core business revenue (instruments and disposables to cell therapy and drug discovery customers and excluding program-related revenue) to grow at least 25% compared to 2021 core business revenue. The company also continue to expect SPL Program-related revenue to be approximately $4 million in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
362 GBX | -0.82% | -2.16% | +2.70% |
05-22 | MaxCyte inks deal with Legend Biotech for tech supply | AN |
05-22 | MaxCyte Signs License Deal With Legend Biotech for Cell Therapy Program | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.70% | 487M | |
+7.87% | 223B | |
+11.83% | 195B | |
+18.87% | 144B | |
+30.03% | 111B | |
+2.32% | 65.19B | |
+14.15% | 53.02B | |
+2.68% | 50.28B | |
+6.60% | 44.15B | |
+1.85% | 36.45B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022